

Beyond the Guidelines:

Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Lymphoma and Chronic Lymphocytic Leukemia

CME Information

TARGET AUDIENCE

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY

Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndrome, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Importantly, currently nearly 70 drug products are labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true within the realm of Hodgkin and non-Hodgkin lymphoma, where the past several years have yielded a staggering number of important clinical and research advances.

Consensus-based guidelines aim to support oncologists and other cancer clinicians in making rational treatment recommendations, but in situations in which multiple “acceptable” therapeutic options exist, such guidelines may not be particularly helpful at the time of decision-making. Because these resources simply enumerate all diagnostic or treatment strategies supported by diverse levels of evidence rather than providing perspectives on the benefits and risks of one strategy versus another, they often leave the clinician alone to contemplate the optimal clinical approach. These proceedings from a CME symposium during the ASH Annual Meeting use an innovative strategy to formally document and present the perspectives, experiences and preferred treatment approaches of 30 lymphoma-specific investigators. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma, including CLL, with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

- Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering clinical presentation, biomarker profile and psychosocial status.
- Appreciate the recent FDA approvals of several novel therapies for the treatment of newly diagnosed and R/R CLL, and discern how these therapies can be appropriately and safely integrated into routine clinical practice.
- Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R follicular, mantle cell and diffuse large B-cell lymphomas.
- Assess the benefits and risks of evidence-based systemic treatment options to optimize the care of patients with peripheral T-cell lymphoma.
- Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
- Develop an understanding of the biologic rationale for and early efficacy and toxicity data with immunotherapeutic approaches for patients with various lymphoma subtypes.
- Assess the ongoing clinical trials evaluating innovative investigational approaches for Hodgkin and non-Hodgkin lymphoma, including CLL, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 3.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHNHL17/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Brad S Kahl, MD

Professor of Medicine
Washington University School of Medicine
St Louis, Missouri

Advisory Committee: Roche Laboratories Inc, Takeda Oncology; **Consulting Agreements:** Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; **Contracted Research:** Abbott Laboratories.

John P Leonard, MD

Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Consulting Agreements: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cephalon Inc.

Gilles A Salles, MD, PhD

Professor of Medicine
Université Claude Bernard
Head of the Hematology Department
Hospices Civils de Lyon
Lyon, France

Advisory Committee: Amgen Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc;

Consulting Agreements: Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

Jeff Sharman, MD

Medical Director of Hematology Research
The US Oncology Network
Director of Research
Willamette Valley Cancer Institute
Eugene, Oregon

Advisory Committee: Acerta Pharma, Celgene Corporation, Genentech BioOncology, Pfizer Inc; **Consulting Agreements:** Acerta Pharma, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Juno Therapeutics, Pfizer Inc; **Contracted Research:** Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Merck, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Roche Laboratories Inc; **Speakers Bureau:** Gilead Sciences Inc.

Julie M Vose, MD, MBA

Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska

Contracted Research: Acerta Pharma, Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Janssen Biotech Inc, Kite Pharma, Seattle Genetics, US Biotest Inc.

Michael E Williams, MD, ScM

Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
University of Virginia
School of Medicine
Charlottesville, Virginia

Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; **Contracted Research:** Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Takeda Oncology.

MODERATOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharma-

ceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the

Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

Hardware/Software Requirements:

A high-speed Internet connection

A monitor set to 1280 x 1024 pixels or more

Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

Adobe Flash Player 10.2 plug-in or later

Adobe Acrobat Reader

(Optional) Sound card and speakers for audio

Last review date: March 2017

Expiration date: March 2018

Select Publications

Brad S Khal, MD

- Awan FT et al. **Acalabrutinib monotherapy in patients with ibrutinib intolerance: Results from the phase 1/2 ACE-CL-001 clinical study.** *Proc ASH 2016;Abstract 638.*
- Barr PM et al. **Updated efficacy and safety from the phase 3 Resonate-2 study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia.** *Proc ASH 2016;Abstract 234.*
- Burger JA et al. **Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.** *N Engl J Med 2015;373(25):2425-37.*
- Byrd JC et al. **Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia.** *N Engl J Med 2016;374:323-32.*
- Byrd JC et al. **Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.** *Blood 2015;125:2497-506.*
- Chen Q et al. **Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States.** *J Clin Oncol 2017;35(2):166-74.*
- Eichhorst B et al. **First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial.** *Lancet Oncol 2016;17(7):928-42.*
- Fischer K et al. **Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial.** *Blood 2016;127(2):208-15.*
- Furman RR et al. **Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.** *N Engl J Med 2014;370:997-1007.*
- Goede V et al. **Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.** *N Engl J Med 2014;370:1101-10.*
- Jones J et al. **Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib.** *Proc ASH 2016;Abstract 637.*
- O'Brien SM et al. **Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia.** *Proc ASH 2016;Abstract 233.*
- Rossi D et al. **Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.** *Blood 2015;126(16):1921-4.*
- Shanafelt T. **Treatment of older patients with chronic lymphocytic leukemia: Key questions and current answers.** *ASH Education Book 2013;2013(1):158-67.*
- Stilgenbauer S et al. **Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study.** *Lancet Oncol 2016;17(6):768-78.*
- Thompson PA et al. **Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.** *Blood 2016;127(3):303-9.*

Gilles A Salles, MD, PhD

- Bachy E et al. **Are we nearing an era of chemotherapy-free management of indolent lymphoma?** *Clin Cancer Res 2014;20:5226-39.*
- Casulo C et al. **Contempo: Preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K- δ , γ inhibitor, duvelisib, in combination with rituximab or obinutuzumab.** *Proc ASH 2016;Abstract 2979.*
- Cheson BD et al. **Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: Updated results of the GADOLIN study.** *Proc ASH 2016;Abstract 615.*
- Flinn IW et al. **Dynamo: A phase 2 study demonstrating the clinical activity of duvelisib in patients with relapsed refractory indolent non-Hodgkin lymphoma.** *Proc ASH 2016;Abstract 1218.*
- Fruman DA et al. **Idelalisib — A PI3K δ inhibitor for B-cell cancers.** *N Engl J Med 2014;370:1061-2.*
- Gopal AK et al. **PI3K δ Inhibition by idelalisib in patients with relapsed indolent lymphoma.** *N Engl J Med 2014;370:1008-18.*
- Marcus RE et al. **Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: Primary results of the randomized phase 3 GALLIUM study.** *Proc ASH 2016;Abstract 6.*

Select Publications

Morschhauser F et al. **A phase Ib study of obinutuzumab combined with lenalidomide for relapsed/refractory follicular B-cell lymphoma.** *Proc ASH* 2014;Abstract 4458.

Patnaik A et al. **First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.** *Ann Oncol* 2016;27(10):1928-40.

Sehn LH et al. **Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial.** *Lancet Oncol* 2016;17(8):1081-93.

Sehn LH et al. **GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.** *Proc ASCO* 2015;Abstract LBA8502.

Sehn LH et al. **Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study.** *J Clin Oncol* 2015;33(30):3467-74.

Jeff Sharman, MD

Behringer K et al. **Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial.** *Lancet* 2015;385(9976):1418-27.

Böll B et al. **Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.** *Blood* 2011;118(24):6292-8.

Chen R et al. **Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.** *Blood* 2016;128(12):1562-6.

Engert A et al. **Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group.** *J Clin Oncol* 2005;23(22):5052-60.

Evens AM et al. **The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496.** *Br J Haematol* 2013;161(1):76-86.

Forero-Torres A et al. **Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.** *Blood* 2015;126(26):2798-804.

Johnson P et al. **Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma.** *N Engl J Med* 2016;374(25):2419-29.

Kolstad A et al. **Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma.** *Leuk Lymphoma* 2007;48(3):570-6.

Moskowitz C et al. **Multicohort phase 2 study of pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R CHL): KEYNOTE-087.** *Proc EHA* 2016;Abstract S794.

Moskowitz CH et al. **Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 2015;385(9980):1853-62.

Yasenchak CA et al. **Brentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: Interim results of a multi-cohort phase 2 study.** *Proc ASH* 2015;Abstract 587.

Younes A et al. **Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial.** *Lancet Oncol* 2016;17(9):1283-94.

Younes A et al. **Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study.** *Lancet Oncol* 2013;14(13):1348-56.

Younes A et al. **Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.** *J Clin Oncol* 2012;30(18):2183-9.

John P Leonard, MD

Chiron D et al. **Cell cycle reprogramming for PI3K inhibition overrides relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.** *Cancer Discov* 2014;4(9):1022-35.

Select Publications

- Davids MS, et al. **Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.** *Proc ASCO* 2014;Abstract 8522.
- Dreyling M et al. **Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** *Ann Oncol* 2014;25(Suppl 3):83-92.
- Fisher RI et al. **Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.** *J Clin Oncol* 2006;24(30):4867-74.
- Goy A et al. **Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study.** *J Clin Oncol* 2013;31(29):3688-95.
- Goy A et al. **Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study.** *Ann Oncol* 2009;20(3):520-5.
- Kluin-Nelemans HC et al. **Treatment of older patients with mantle-cell lymphoma.** *N Engl J Med* 2012;367(6):520-31.
- Le Gouill S et al. **Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: Final results of the randomized phase 3 LyMa trial of the Lysa/Goelams Group.** *Proc ASH* 2016;Abstract 145.
- Leonard J P et al. **Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.** *Blood* 2012;119:4597-607.
- Martin P et al. **A phase I trial of ibrutinib plus palbociclib in patients with previously treated mantle cell lymphoma.** *Proc ASH* 2016;Abstract 150.
- Martin P et al. **Postibrutinib outcomes in patients with mantle cell lymphoma.** *Blood* 2016;127(12):1559-63.
- Ruan J et al. **Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma.** *N Engl J Med* 2015;373:1835-44.
- Rummel MJ et al. **Two years rituximab maintenance vs observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).** *Proc ASCO* 2016;Abstract 7503.
- Wang ML et al. **Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.** *Blood* 2015;126(6):739-45.
- Michael E Williams, MD, ScM**
- Dave SS et al. **Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.** *N Engl J Med* 2004;351(21):2159-69.
- Dunleavy K et al. **Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: Do they require a unique therapeutic approach?** *Blood* 2015;125(1):33-39.
- Habermann TM et al. **Treatment and clinical outcomes of high grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (double hit/triple hit lymphomas).** *Proc ASH* 2016;Abstract 155.
- Hans CP et al. **Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.** *Blood* 2004;103:275-82.
- Johnson NA et al. **Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.** *J Clin Oncol* 2012;30(28):3452-9.
- Kochenderfer JN et al. **Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.** *J Clin Oncol* 2015;33(6):540-9.
- Lenz G et al. **Stromal gene signatures in large-B-cell lymphomas.** *N Engl J Med* 2008;359(22):2313-23.
- Lesokhin AM et al. **Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study.** *J Clin Oncol* 2016;34(23):2698-704.
- Maude SL et al. **CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.** *Blood* 2015;125:4017-23.
- Neelapu SS et al. **Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): Results from the pivotal phase 2 ZUMA-1.** *Proc ASH* 2016;Abstract LBA-6.

Select Publications

- Oki U et al. **Double hit lymphoma: The MD Anderson Cancer Center clinical experience.** *Br J Haematol* 2014;166(6):891-901.
- Rosenwald A et al. **The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.** *N Engl J Med* 2002;346(25):1937-47.
- Schuster SJ et al. **Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas.** *Proc ASH* 2015;Abstract 183.
- Scott DW et al. **Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.** *J Clin Oncol* 2015;33:2848-56.
- Scott DW et al. **Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.** *Blood* 2014;123:1214.
- Staiger AM et al. **The clinical impact of the cell-of-origin classification and the MYC+/BCL2+ double expresser status in DLBCL treated within prospective clinical trials of the DSHNHL.** *Proc ASH* 2016;Abstract 151.
- Younes A et al. **Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study.** *Lancet Oncol* 2014;15(9):1019-26.
- Zinzani PL et al. **Phase 1b study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma: Results from the ongoing Keynote-013 trial.** *Proc ASH* 2016;Abstract 619.

Julie M Vose, MD, MBA

- Coiffier B et al. **Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.** *J Clin Oncol* 2012;30(6):631-6.
- Crescenzo R et al. **Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.** *Cancer Cell* 2015;27(4):516-32.
- Damaj G et al. **Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial.** *J Clin Oncol* 2013;31:104-10.
- Foss FM et al. **Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): First detailed report of primary treatment.** *Blood* 2012;120(21):1614.
- Gambacorti Passerini C et al. **Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.** *J Natl Cancer Inst* 2014;106(2):djt378.
- Horwitz SM et al. **Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.** *Blood* 2014;123(20):3095-100.
- Horwitz S et al. **Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): Results from the pivotal BELIEF trial.** *Proc ICML* 2013;Abstract 153.
- Iqbal J et al. **Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?** *Blood Rev* 2016;30(2):89-100.
- Lunning MA et al. **A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.** *Proc ASCO* 2014;Abstract 8582.
- Lunning MA et al. **Strategies for relapsed peripheral T-cell lymphoma: The tail that wags the curve.** *J Clin Oncol* 2013;31(16):1922-7.
- Mak V et al. **Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors.** *J Clin Oncol* 2013;31:1970-6.
- Morschhauser F et al. **A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial.** *Eur J Cancer* 2013;49(13):2869-76.
- O'Connor OA et al. **Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).** *Proc ASCO* 2013;Abstract TPS8611.
- O'Connor OA et al. **Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study.** *J Clin Oncol* 2011;29:1182-9.

Select Publications

Pro B et al. **Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study.** *J Clin Oncol* 2012;30(18):2190-6.

Sakata-Yanagimoto M et al. **Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.** *Nat Genet* 2014;46(2):171-5.

Savage KJ et al. **Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.** *Ann Oncol* 2004;15(10):1467-75.

Vose JM et al. **International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes.** *J Clin Oncol* 2008;26:4124-30.